Pune, India — 02/06/2018 — Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan) are some of the leading players at the cutting edge of the competition in the Diabetes Drug Market, globally.
Diabetes occurs when the pancreas are not able to produce enough insulin to get body glucose into the cells. This shortage of insulin roots sugar to build up in the blood. According to the report published by International Diabetes Federation, in 2016, it was evaluated that 420 million adult population were suffering with diabetes. If the patients' population will grow with the same phase it was projected that around 625 million people will suffer with the disease by 2040, at a rate of 8.4%.
Get a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1160 .
Global Diabetes Drugs Market â€“ Overview
The global diabetes drugs market is growing with a swift phase; mainly due to increase in patient population and research and development done by market players to fill the gap of market. The WHO estimated that diabetes leads to 1.6 million deaths in 2015 and it is the major causes of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Increase in incidence of chronic disease owing to diabetes will drag the interest of biopharmaceutical researchers for developing effective drugs for the treatment. More than 170 diabetes drugs are in the development stage to cure diabetes or diabetes related conditions. In 2014, the cost of diabetes diagnosis was around USD 245 billion in the United States, and biopharmaceutical researchers are focusing to find new lifesaving and life-changing treatments.
Companies are continuously engaged in merger and acquisition activities for the development of best medicine to cure affected diabetes population. In this regard, Merck & Co. and Pfizer are continuously working together from last four years to introduce best product and finally four year old alliance has reached fruition with the filling of three new products in year 2017. These companies was working together since 2013, and announced that studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in evolution to help control glucose level in adults with type 2 diabetes, met their primary endpoints. The reviewing is now ongoing at the FDA and EMA, and the two market players will get the approval by the end of this year, saying that the trio of ertugliflozin products will provide add on option for treatment of type 2 diabetics. Merck and Pfizer hope to fill the gap of market along with leaders such as Novo Nordisk, Abbott, AstraZeneca, Biocon, Sanofi, and Novartis.
Check Attractive Discount @ https://www.marketresearchfuture.com/check-discount/1160 .
Top five selling Diabetes Drugs, 2016
Increase in the prevalence of diabetes around the globe is creating the huge scope for the market players to earn profit. These are the top five drugs that create significant revenue in 2016. Lantus is the drug introduce by Sanofi, and capture the highest market share with total sales of USD 3.9 billion followed by Januvia introduce by Merck & Co. with the sales of USD 2.29 billion. Victoza and Levemir hold the third and fourth position in global sales with USD 2.10 billion and USD 1.82 billion respectively. Humalog hold the fifth position with USD 1.69 billion. Introduce by Eli Lilly and Company.
Market Factor Analysis
Global Diabetes Drug Market, by Type
Global Diabetes Drug Market, by Administration
Global Diabetes Drug Market, by End User
Global Diabetes Drug Market, by End User
Global Diabetes Drug Market, by Region
Ask to Expert @ https://www.marketresearchfuture.com/enquiry/1160 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Latest posts by Editorial Team (see all)
- American Academy of Thermology 2018 Annual Scientific Session Awarded 6.5 hours of AMA PRA Category 1 CME - May 20, 2018
- Strong Programme Raises Profile of the Maritime Standard Ship Finance and Trade Conference - May 20, 2018
- Pegasus Food Futures Announces Appointment of Stefanie Paterson as Head of Human Resources - May 20, 2018